Cti Biopharma Corp Stock
Your prediction
Pros and Cons of Cti Biopharma Corp in the next few years
Pros
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cti Biopharma Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cti Biopharma Corp | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | -0.900% | -2.146% | 76.744% | 78.125% | 37.349% | -21.379% | -65.714% |
| Vaxart Inc. | 0.000% | 2.727% | 31.395% | 29.945% | 101.786% | -30.912% | -87.500% |
| Celldex Therapeutics | -0.790% | -2.326% | 23.529% | 24.752% | 14.545% | -41.423% | 28.114% |
Comments
CTI BioPharma Corp. (NASDAQ: CTIC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
Show more
Ratings data for CTIC provided by MarketBeat
CTI BioPharma Corp. (NASDAQ: CTIC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
Show more
Ratings data for CTIC provided by MarketBeat
